Ahmet ADIGUZEL, Unal OZTURK, Sibel ALTINAYAR

Parkinson's Disease Profile – A 17-Year Patient Analysis

causes disability in advanced stages. The main pathology is the degeneration of the basal ganglia, especially the substantia nigra. In the clinic, motor and non-motor findings (NMF) are seen, and treatment approach is symptomatic. Factors that increase the risk in Parkinson's disease are male gender, old age, white race, environmental conditions, trauma, vascular diseases, family history, and genetic mutations. In this study, idiopathic Parkinson's patients who came to our movement disorders outpatient clinic in the last 17 years were evaluated retrospectively. We aimed to determine the IPD profile in our region through demographic and clinical findings and treatments used and compare the results with the literature. Methods: We evaluated 1150 patients admitted to the neurology department of movement disorders outpatient clinic due to parkinsonism. Five hundred seventy-eight patients with IPD were included in the study. Demographic data such as age, sex, place of birth, place of residence (rural/urban), comorbidities, family history, and habits were recorded. Results: A total of 63.5% of the patients were male. The mean age of the patients was 68.51(SD ± 10.35) years old for males and 68.37(SD ± 11.22) years old for females, 62.61(SD ± 11.31) for males and 62.55(SD ± 12.46) for females. 66.4% of the patients had the first clinical finding as tremor, while 55.4% had the tremor as the leading complaint. It was seen that 57% of the patients had NMF. It was observed that 52.8% of the patients did not have dementia. As the clinical stage progressed, it was determined that there was a significant increase in dementia rate. Hypertension (HT) (M/F%:35,2/47,2 p=0.01) and thyroid diseases (M/F%:2.3/10.3 p=0,00) were more frequent in female patients than in male patients. Impulsive-compulsive behaviors (ICBs) which are treatment-related problems were more common in males than in females (M/F%:17.8/8.5 p=0,00). Conclusion: The results were found to be similar to the literature. In this study, we have noticed the neglected, incomplete, or inadequately questioned parameters in routine-intensive outpatient conditions. Taking these results into consideration, we had the opportunity to correct our shortcomings in our future studies.

PDF

___

1. Bekris LM, Mata IF, Zabetian CP. The Genetics of Parkinson Disease, Journal of Geriatric Psychiatry and Neurology. 2010; 23: 228–42.
2. Arikanoglu A, Hunkar R, Cınar K. Parkinsonism secondary to bilateral subdural hematoma. Dicle Med J. 2011; 38: 247-9.
3. Kalia LV, Lang AE. Parkinson disease in 2015: Evolving basic, pathological and clinical concepts in PD. Nat Rev Neurol. 2016; 12: 65–6.
4. Gaare JJ, Skeie GO, Tzoulis C, Larsen JP, Tysnes OB. Familial aggregation of Parkinson's disease may affect progression of motor symptoms and dementia. Movement disorders: official Journal of the Movement Disorder Society. 2017; 32: 241-45.
5. Breckenridge CB, Berry C, Chang ET, Sielken Jr RL, Mandel JS. Association between Parkinson’s Disease and Cigarette Smoking, Rural Living, Well-Water Consumption, Farming and Pesticide Use: Systematic Review and Meta-Analysis. PloS one. 2016; 11: e0151841.
6. Ritz B, Lee PC, Lassen CF, Arah OA. Parkinson disease and smoking revisited: ease of quitting is an early sign of the disease. Neurology. 2014; 83: 1396–402.
7. PD MED Collaborative Group. Long-term eff ectiveness of dopamine agonists and monoamine oxidase B inhibitors compared with levodopa as initial treatment for Parkinson’s disease (PD MED): a large, open-label, pragmatic randomised trial. Lancet. 2014; 384: 1196– 205.
8. Martin I, Dawson VL, Dawson TM. Recent advances in the genetics of Parkinson's disease. Annu Rev Genomics Hum Genet. 2011; 12: 301–25.
9. Driver JA, Logroscino G, Gaziano JM, Kurth T. Incidence and remaining lifetime risk of Parkinson disease in advanced age. Neurology. 2009; 72: 432–8.
10. Pringsheim T, Jette N, Frolkis A, Steeves TDL. The prevalence of Parkinson’s disease: a systematic review and meta-analysis. Mov Disord. 2014; 29: 1583–90.
11. Benito-León J1, Bermejo-Pareja F, Rodríguez J, et al. Prevalence of PD and other types of parkinsonism in three elderly populations of central Spain Neurological Disorders in Central Spain (NEDICES) Study Group. Mov disord. 2003; 18: 267-74.
12. Picillo M, Nicoletti A, Fetoni V, et al. The relevance of gender in Parkinson's disease: a review. J Neurol. 2017 Aug; 264(8): 1583-1607. doi: 10.1007/s00415-016- 8384-9. Epub 2017 Jan 4.
13. Noyce AJ, Bestwick JP, Silveira-Moriyama L, et al. Meta-analysis of early nonmotor features and risk factors for Parkinson disease. Ann Neurol. 2012; 72: 893–901.
14. Belvisi D, Conte A, Bologna M, et al. Re-emergent tremor in Parkinson's disease, Parkinsonism Relat Disord. 2016; 36: 41-46. http://dx.doi.org/10.1016/j.parkreldis. 2016.12.012.
15. Martin WE, Loewenson RB, Resch JA, Baker AB. Parkinson’s disease: clinical analysis of 100 patients. Neurology. 1983; 23: 783-90.
16. Beiske AG, Loge JH, Rønningen A, Svensson E. Pain in Parkinson’s disease: Prevalence and characteristics. Pain. 2009; 141: 173-7. doi: 10.1016/j.pain.2008.12.004.
17. Hanagasi HA, Akat S, Gurvit H, Yazici J, Emre M. Pain is common in Parkinson's disease. Clinical Neurology and Neurosurgery Clin Neurol Neurosurg. 2011 Jan; 113: 11- 13. doi: 10.1016/j.clineuro.2010.07.024.
18. Yoritaka A, Ohizumi H, Tanaka S, Hattori N. Parkinson’s disease with and without REM sleep behaviour disorder: are there any clinical differences? Eur Neurol. 2009; 61: 164-70.
19. Howell MJ, Schenck CH. Rapid eye movement sleep behavior disorder and neurodegenerative disease. JAMA Neurol. 2015; 72: 707-12.
20. Doty RL. Olfaction in Parkinson’s disease and related disorders. Neurobiol Dis. 2012; 46: 527–52.
21. Postuma RB, Gagnon JF, Vendette M, Desjardins C, Montplaisir JY. Olfaction and color vision identify impending neurodegeneration in rapid eye movement sleep behavior disorder. Ann Neurol 2011; 69: 811–8.
22. Altinayar S, Oner S, Can S, Kizilay A, Kamisli S, Sarac K. Olfactory disfunction and its relation olfactory bulb volume in Parkinson's disease. Eur Rev Med Pharmacol Sci. 2014; 18: 3659-64.
23. Knudsen K, Krogh K, Østergaard K, Borghammer P. Constipation in Parkinson’s disease: Subjective symptoms, objective markers, and new perspectives. Movement Disorders. 2017; 32: 94–105.
24. Khedr EM, Fetoh El NA, Khalifa H, Ahmed MA, Beh El KM. Prevalence of non-motor features in a cohort of Parkinson’s disease patients. Clinical Neurology and Neurosurgery. 2013; 115: 673–7.
25. Pont-Sunyer C, Hotter A, Gaig C, et al. The onset of nonmotor symptoms in Parkinson’s disease (the ONSET PD study). Movement Disorders. 2015; 30: 229–37.
26. Monchi O, Hanganu A, Bellec P. Markers of cognitive decline in PD: The case for heterogeneity. Parkinsonism & Related Disorders. 2016; 24: 8-14.
27. Buter TC, van den Hout A, Matthews FE, et al. Dementia and survival in Parkinson disease: a 12-year population study. Neurology. 2008; 70: 1017-22.
28. Parkinson Study Group. Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. Archives of Neurology. 2004; 61: 1044-53.
29. Violante MR, Latapi PG, Arriaga AC, Ordonez AC, Weintraub D. Impulse control and related disorders in Mexican Parkinson’s disease patients. Parkinsonism and Related Disorders. 2014; 20: 907-10.
30. Cilia R, Siri C, Canesi M, et al. Dopamine dysregulation syndrome in Parkinson’s disease: from clinical and neuropsychological characterisation to management and long-term outcome. J Neurol Neurosurg Psychiatry. 2014; 85: 311–8.